Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray

BMC Cancer

Research Article

Karin Jirström¹  Kristina Lövgren²  Elin Möllerström³  Ulla Delle³  Toshima Parris³  Anna Danielsson³  Khalil Helou³  Per Karlsson⁴  Szilard Nemes⁵  Anikó Kovács⁶  Donal J Brennan⁷ 

[1] Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, University Hospital MAS, Malmö, Sweden;Department of Oncology, Barngatan 2:2, Lund University Hospital, University of Lund, SE-221 85, Lund, Sweden;Department of Oncology, Institute of Clinical Sciences, Blå stråket 2, University of Gothenburg, SE-413 45, Göteborg, Sweden;Department of Oncology, Sahlgrenska University Hospital, Blå stråket 2, University of Gothenburg, SE-413 45, Göteborg, Sweden;Division of Clinical Cancer Epidemiology, Department of Oncology, Sahlgrenska Academy, University of Gothenburg, Sweden;Pathology section, Department of Pathology, Sahlgrenska University Hospital, Blå stråket 2, University of Gothenburg, SE-413 45, Göteborg, Sweden;UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland;

关键词: Breast Cancer;    Breast Cancer Patient;    Ki67 Expression;    Hormone Receptor Status;    HER2 Expression;   

DOI  :  10.1186/1471-2407-10-296

 received in 2009-09-29, accepted in 2010-06-16,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundPrevious studies have shown that the ADIPOR1, ADORA1, BTG2 and CD46 genes differ significantly between long-term survivors of breast cancer and deceased patients, both in levels of gene expression and DNA copy numbers. The aim of this study was to characterize the expression of the corresponding proteins in breast carcinoma and to determine their correlation with clinical outcome.MethodsProtein expression was evaluated using immunohistochemistry in an independent breast cancer cohort of 144 samples represented on tissue microarrays. Fisher's exact test was used to analyze the differences in protein expression between dead and alive patients. We used Cox-regression multivariate analysis to assess whether the new markers predict the survival status of the patients better than the currently used markers.ResultsBTG2 expression was demonstrated in a significantly lower proportion of samples from dead patients compared to alive patients, both in overall expression (P = 0.026) and cell membrane specific expression (P = 0.013), whereas neither ADIPOR1, ADORA1 nor CD46 showed differential expression in the two survival groups. Furthermore, a multivariate analysis showed that a model containing BTG2 expression in combination with HER2 and Ki67 expression along with patient age performed better than a model containing the currently used prognostic markers (tumour size, nodal status, HER2 expression, hormone receptor status, histological grade, and patient age). Interestingly, BTG2 has previously been described as a tumour suppressor gene involved in cell cycle arrest and p53 signalling.ConclusionsWe conclude that high-level BTG2 protein expression correlates with prolonged survival in patients with breast carcinoma.

【 授权许可】

CC BY   
© Möllerström et al; licensee BioMed Central Ltd. 2010